AprilBio completes 141.8 billion won third-party allocation capital increase, issuing 17.5% new shares, raising dilution concerns for existing shareholders

AprilBio completed a third-party allocation capital increase of 141.8 billion won with a payment date of July 23, 2026.
The newly issued shares total 4,095,456 shares, representing a 17.5% dilution of existing shares, and are subject to a one-year lock-up period.
The issue price of 34,627 won is approximately 41% above the current market price of 24,500 won, reflecting a premium, but the massive dilution is expected to exert downward pressure on the stock price.
Simultaneously, a management change contract was signed, warranting attention to potential governance shifts.
[AI Summary]AprilBio's capital increase represents a structural change involving significant dilution and a change in control. While the issue price premium is positive, the 17.5% share issuance substantially impairs existing shareholder value, likely negatively impacting short-term stock performance.